Angiotech Launches Orthopedics Strategy With Orthovita Pact, NeuColl Buy
This article was originally published in The Gray Sheet
Executive Summary
Angiotech's marketing agreement with Orthovita for its CoStasis hemostatic spray, and NeuColl purchase, provide an initial orthopedics presence as the firm develops drug/device combinations for the sector